Akero Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$0.83 | -$0.83 | -$0.83 |
| Q2 2024 | 2 | -$0.88 | -$0.88 | -$0.88 |
| Q3 2024 | 6 | -$1.21 | -$1.11 | -$1.16 |
| Q1 2025 | 4 | -$1.14 | -$1.10 | -$1.12 |
| Q2 2025 | 2 | -$1.12 | -$1.12 | -$1.12 |
| Q3 2025 | 2 | -$1.22 | -$1.22 | -$1.22 |
| Q4 2025 | 2 | -$1.26 | -$1.26 | -$1.26 |
Akero Therapeutics, Inc. Earnings Date And Information
Akero Therapeutics, Inc. last posted its earnings results on Friday, November 8th, 2024. The company reported $-1.05 earnings per share for the quarter, missing analysts' consensus estimates of $-0.9 by $0.15. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Akero Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.89 diluted earnings per share) and currently has a price-to-earnings ratio of -8.97. Akero Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based on prior year's report dates.
Akero Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/08/2024 | Q3 2024 | -$0.90 | -$1.05 | -0.15 | $0 | $0 |
| 08/09/2024 | Q2 2024 | -$0.90 | -$0.81 | 0.09 | $0 | $0 |
| 05/10/2024 | Q1 2024 | -$0.90 | -$0.90 | 0 | $0 | |
| 02/29/2024 | Q4 2023 | -$0.82 | -$0.99 | -0.17 | $284,000 | |
| 11/13/2023 | Q3 2023 | -$0.71 | $0 | |||
| 08/10/2023 | Q2 2023 | -$0.62 | -$0.60 | 0.02 | $0 | |
| 05/15/2023 | Q1 2023 | -$0.62 | -$0.50 | 0.12 | $0 | |
| 03/17/2023 | Q4 2022 | -$0.78 | -$0.44 | 0.34 | $0 | |
| 11/04/2022 | Q3 2022 | -$0.73 | -$0.91 | -0.18 | $0 | |
| 08/04/2022 | Q2 2022 | -$0.77 | $0 | |||
| 05/06/2022 | Q1 2022 | -$0.85 | -$0.74 | 0.11 | $0 | |
| 02/25/2022 | Q4 2021 | -$0.81 | -$0.93 | -0.12 | $0 | |
| 11/12/2021 | Q3 2021 | -$0.91 | -$0.70 | 0.21 | $0 | |
| 08/13/2021 | Q2 2021 | -$0.72 | -$0.83 | -0.11 | $0 | |
| 05/13/2021 | Q1 2021 | -$1.01 | -$0.43 | 0.58 | $0 | |
| 03/16/2021 | Q4 2020 | -$0.72 | -$0.86 | -0.14 | $0 | |
| 11/12/2020 | Q3 2020 | -$0.48 | -$0.63 | -0.15 | $0 | |
| 08/12/2020 | Q2 2020 | -$0.48 | -$0.57 | -0.09 | $0 | |
| 05/13/2020 | Q1 2020 | -$0.60 | -$0.42 | 0.18 | $0 | |
| 03/16/2020 | Q4 2019 | -$0.59 | -$0.55 | 0.04 | $0 |
Akero Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Akero Therapeutics, Inc.'s earnings date?
Akero Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates.
-
How can I listen to Akero Therapeutics, Inc.'s earnings conference call?
The conference call for Akero Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Akero Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Akero Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Akero Therapeutics, Inc. generate each year?
Akero Therapeutics, Inc. (:AKRO) has a recorded net income of $0. Akero Therapeutics, Inc. has generated $-2.89 earnings per share over the last four quarters.
-
What is Akero Therapeutics, Inc.'s price-to-earnings ratio?
Akero Therapeutics, Inc. (:AKRO) has a price-to-earnings ratio of -8.97 and price/earnings-to-growth ratio is 0.9.
